Trial NCT04631601

View at ClinicalTrials.gov 
Org. Study IDs: 20190505
Secondary IDs: 2020-001305-23

Last trial update was posted on 2023-11-07

MeSH Interventions

Androgen Receptor Antagonists Androgens Immune Checkpoint Inhibitors

MeSH Conditions

Prostatic Neoplasms

Other Conditions

Metastatic Castration-resistant Prostate Cancer

Stopping Reasons

Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID